Past, Present
and Future
History
Better Life with VIVOZON
New drug development experts have worked together for a healthy future
2008
2012
2013
2016
2017
Current
2008~2012
Passion
for progress
Securing the foundation of a company
- 2008
-
Establishment of Vivozon and certification of company-affiliated research institute
- 2009
-
Establishment of a multi-target drug development platform
Identification of non-narcotic analgesic, VVZ-149
- 2010
-
Initiation of non-clinical studies of VVZ-149
Patent registration of pain clinical testing method (Korea)
- 2011
-
Selection as a non-clinical project for innovative drug development by the Korean Ministry of Health and Welfare (2013 best project evaluation)
- 2012
-
Registration of substance patent, VVZ-149 (Korea/US/EU/Japan/India/China)
2013~2016
Challenge
for innovation
Setting the main pipeline
- 2013
-
Approval from the Ministry of Food and Drug Safety for Phase 1 clinical trial of VVZ-149
Selection as phase 1 clinical project for innovative drug development
by the Ministry of Health and Welfare (2015 best project evaluation)
- 2014
-
Receipt of Secretary’s Award from the Korean Minister of Health and Welfare
- 2015
-
Approval from the Ministry of Food and Drug Safety for phase 2 clinical trial of VVZ-149
Approval from US FDA for phase 2 clinical trial of VVZ-149
Registration of Substance Patent, VVZ-149 (Korean)
Selection as phase 2 clinical project for innovative drug development by the Ministry of Health and Welfare (2018 best project evaluation)
Selection as project from the Korea Medical Device Development Fund (VVZ-149 oral drug development)
- 2016
-
Registration of substance patent, VVZ-149 (US)
Establishment of Vivozon US, a local corporation in the United States
2017~Current
Towards a
global Challenge
Business expansion and leap forward
- 2017
-
Establishment of the Yongin Innovative New Drug Research Institute ‘Vivozon Medical Biology Research Center’
Establishment of Vivozon Canada, a local corporation in Canada
Registration of substance patent, VVZ-149 (China/Japan)
Merge of Telecon Life Sciences
Registration of substance patent, VVZ-149 (Europe)
- 2018
-
Registration of K-OTC
US FDA fast track designation
US FDA report meeting on completion of phase 2 clinical trial, VVZ-149 (End of Phase 2 Meeting)
- 2019
-
Approval and completion from US FDA for phase 3 clinical trial of VVZ-149
Approval for external application for phase 1/2a clinical trial of VVZ-149 by the Ministry of Food and Drug Safety
Derivation of top line for VVZ-149 clinical phase 2b and 3a for injection
- 2020
-
Acquisition of Lumi Micro (*name changed to Vivozon Healthcare)
Acquisition of Ihu investment (*name changed to Clairvoyant Ventures)
Acquisition of Vivozon Healthcare and Inist Biopharmaceutical (*name changed to Vivozon Pharmaceutical)
- 2021
- 2022
- 2023
